Track market-moving stories before they get noisy

Evernorth, a company aiming to become the first publicly traded XRP treasury, is approaching a key milestone as it awaits a final shareholder vote to move forward with its public listing plans. The development has drawn attention from the cryptocurrency community, particularly after a recent statement by crypto analyst Dark Defender, who suggested that major changes could be ahead for XRP’s market dynamics.

Evernorth’s proposed transition to a public company centers around its business combination with Armada Acquisition Corp. II, a special purpose acquisition company listed on the stock market. Following recent regulatory steps, the combined entity would become one of the first public companies with a primary treasury focus on XRP, the digital asset developed by Ripple Labs.

On August 27, the US Securities and Exchange Commission (SEC) declared effective Evernorth’s Form S-4 registration statement, clearing a compliance hurdle but not signaling endorsement of the business model, the merger, or XRP as a security or investment. This action allows Armada’s shareholders to vote on the proposed transaction.

The shareholder vote is scheduled for September 30, 2026. If the remaining closing requirements are met and shareholders approve, Evernorth expects to begin publicly trading on Nasdaq under the ticker XRPN.

Dark Defender described these developments as bringing Evernorth “one shareholder vote away” from trading on Nasdaq, but noted that the listing is still conditional on completing all necessary steps.

Publicly available transaction documents show that Evernorth could begin with approximately 473 million XRP as its treasury holding if the plan is approved.

Evernorth’s major backers include Ripple, the founding company behind XRP, as well as Arrington Capital, SBI Group, Pantera Capital, Kraken, and GSR.

Mini dictionary: Armada Acquisition Corp. II – A special purpose acquisition company (SPAC) is a publicly listed firm formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company and taking it public without a traditional IPO process.

EventDateStatusSEC Form S-4 effectivenessAugust 27, 2026CompletedShareholder vote (Armada)September 30, 2026PendingExpected Nasdaq listingPost-approvalNot completedAnalyst highlights potential XRP supply impactCrypto analyst Dark Defender, who regularly comments on XRP market trends, linked Evernorth’s transition to the possibility of an XRP supply shock. In a series of social media posts, he referenced the recent SEC milestone and noted Evernorth’s apparent shift from quietly accumulating XRP to a more public-facing approach.

Dark Defender pointed to messages from the company, including a teaser that “someone new will be joining the Evernorth story,” interpreting this as a sign that its initial accumulation phase may be ending.

He observed, “A treasury (Evernorth) has one job: buying quietly. But they started teasing. You only start talking when the quiet part is done.”

He concluded by predicting that “an XRP supply shock is inevitable,” though this perspective remains an analyst’s view and is not confirmed by Evernorth.

Outlook for Nasdaq listing and XRP marketIf the business combination is approved and Evernorth lists on Nasdaq, public investors will gain exposure to a company holding a significant amount of XRP and pursuing growth strategies linked to the XRP ecosystem. The company’s business plan includes not only holding XRP but deploying capital into projects and infrastructure built around the asset, aiming to increase its value and utility.

Any supply reduction in available XRP on the market would depend on the scale and pace of Evernorth’s purchases, overall market liquidity, and future decisions regarding its treasury management. The timing and impact of such changes are still uncertain and will be closely monitored by market participants.

한국어로 보기

Standard Chartered has expanded its regulated digital asset business in the United Arab Emirates (UAE) with spot Bitcoin and Ethereum trading for institutional clients, adding the service to a regional crypto offering that already includes custody.

The London-headquartered bank introduced digital asset custody in the UAE in September 2024. In June 2026, it followed with a banking agreement allowing CoinMENA to use Standard Chartered for fiat on- and off-ramps, client money accounts and transaction management through virtual accounts.

The bank is providing the new service through Standard Chartered DIFC, an entity regulated by the Dubai Financial Services Authority (DFSA).

Institutional Clients Gain Spot Crypto Access Eligible institutions can access spot Bitcoin (BTC) and Ethereum (ETH) trading through electronic trading channels integrated into Standard Chartered’s existing platforms.

Standard Chartered said Thursday that it is the first Global Systemically Important Bank (G-SIB) to offer the capability in the UAE and the only global bank currently providing institutional digital asset spot trading in the region.

Other Platforms Seek UAE Crypto Approvals The launch comes amid broader efforts by cryptocurrency and trading businesses to secure regulatory authorization for digital asset products in the UAE.

Capital.com disclosed plans in August to provide spot crypto services to UAE clients after its affiliate, Capital Vault UAE, obtained a virtual-asset licence from the country’s Capital Market Authority (CMA).

Revolut also moved to expand its crypto services in July, when the neobank received in-principle approval from Dubai’s Virtual Assets Regulatory Authority to provide crypto-related services in the UAE.

DisClamier: This content is informational and should not be considered financial advice. The views expressed in this article may include the author's personal opinions and do not reflect The Crypto Basic opinion. Readers are encouraged to do thorough research before making any investment decisions. The Crypto Basic is not responsible for any financial losses.

Following its public testnet phase, RealFi has set the launch date for its decentralized finance (DeFi) platform on the Cardano mainnet.

The RealFi team announced the date while providing an update on its Pioneer Season, which has served as a testing and feedback phase ahead of the mainnet rollout. According to the team, the platform will officially launch on Cardano on October 1, 2026.

Update on RealFi Pioneer Season   Notably, the team noted that more than 3,600 users have participated in RealFi’s Pioneer Season, completing over 40,000 quest actions on the public testnet.

The team said the testnet provided valuable insights into how users interact with the platform while helping developers identify areas for improvement. Rather than serving as a simple demonstration, the Pioneer Season allowed RealFi to collect real user activity and community feedback and use those insights to refine the platform ahead of its mainnet debut.

RealFi also clarified that the Pioneer Season will continue until the mainnet launch. However, the extension does not reflect any major problem or setback.

Instead, the team plans to use the additional time to incorporate community feedback and strengthen the platform’s overall readiness. RealFi said it wants to make the transition to mainnet as smooth and polished as possible, with more details about the launch and changes for Pioneer participants expected closer to October.

RealFi Targets Real-World Finance on Cardano RealFi (Real Finance) aims to connect Cardano’s cryptocurrency liquidity with real-world financial activities and assets. Its broader vision includes microloans, real-world asset-backed financial products, and yield generated from productive economic activity rather than purely speculative trading.

The ecosystem’s key products include USDr, a Cardano-native dollar-pegged stablecoin backed by real-world assets, and sUSDr, a yield-bearing asset designed to generate returns from the underlying real-world asset portfolio. 

Hoskinson Expects RealFi to Boost Cardano TVL  Meanwhile, Cardano founder Charles Hoskinson also retweeted the latest announcement, signaling his support for the project. In a recent commentary, Hoskinson highlighted RealFi as one of the initiatives that could help drive Cardano’s next phase of growth. He believes the platform could attract billions of dollars into the Cardano ecosystem.

According to Hoskinson, users deposit assets into RealFi’s smart contracts, where the funds remain locked while generating yield. As participation grows, these deposits can increase Cardano’s total value locked (TVL), while deposits, withdrawals, and yield distributions also generate additional on-chain activity. In the meantime, Cardano’s TVL currently stands at $64.23 million, up 4.99% over the past 24 hours. 

DisClamier: This content is informational and should not be considered financial advice. The views expressed in this article may include the author's personal opinions and do not reflect The Crypto Basic opinion. Readers are encouraged to do thorough research before making any investment decisions. The Crypto Basic is not responsible for any financial losses.

The S&P 500 (^GSPC +0.46%) currently has a dividend yield of around 1%. Investing in the S&P 500 via index funds has historically produced solid long-term total returns, but for income investors, it's not necessarily the right vehicle for their specific objectives.

However, don't assume you need to trade stability for yield. Among Dividend Kings, or stocks with 50 years or more of consecutive dividend growth, there are stocks yielding considerably more than the market index.

A prime example of this is with Federal Realty Investment Trust (FRT +0.78%). Currently trading for around $116 per share, this real estate investment trust (REIT) has a nearly 4% forward dividend yield, practically quadruple that of the S&P 500.

Image source: Getty Images.

Portrait of a venerable REIT stock Federal Realty Investment Trust was one of the first REITs. It was founded in 1962, not too long after legislation allowing for REITs was first signed into U.S. law. Having raised its dividend for 59 consecutive years, it's one of the Dividend Kings, the first and, for now, only REIT to hold this status.

Why has this REIT achieved this status, while other REITs, including those formed at the same time as Federal Realty Investment Trust, have not? Chalk it up to its focus on high-quality retail properties, located in markets such as Boston, New York, Washington, D.C., Silicon Valley, and Southern California, markets known for high real estate values, land scarcity, and, as this REIT itself puts it, "high barriers to entry."

A look at Federal Realty Investment Trust's latest financials underscores its status. In the quarter ending June 30, 2026, the REIT reported overall portfolio occupancy of 93.8% and a leased rate of 96.1%. Core funds from operations (FFO), the REIT equivalent of adjusted operating cash flow, increased 6.8% year over year. Reported Nareit FFO declined by 1.6%, but only because of a one-time tax-related item that raised reported results during Q2 2025. In the Q2 2026 earnings release, management inched up guidance and announced plans to increase its regular quarterly cash dividend by 3%.

The takeaway for all investors For income investors, Federal Realty Investment Trust offers a nearly 4% yield, with a dividend growth track record suggesting its yield on cost will gradually rise over time. Add in the impact of inflation and redevelopment on this REIT's value over time, and there's strong potential for long-term capital appreciation as well.

This latter opportunity makes this a REIT for investors focused more on capital growth than portfolio income. In terms of dividend sustainability, with core FFO to come in between $7.48 and $7.56 per share this year, against $4.64 per share in total annual dividends, the stock effectively has a forward payout ratio of between 61% and 62%, leaving the REIT well positioned to keep paying investors quarterly, all while reinvesting and growing its property portfolio.

That said, it's not as if this REIT is a no-risk alternative to the S&P 500. Dividend growth has slowed in recent years. The 2020s rate hikes both negatively affected stock price performance and increased interest expenses, weighing on the bottom line. Nevertheless, normalizing macro conditions could temper these risks, getting dividend growth and price appreciation back on track.

Emerald Investment Advisers LLC acquired a new position in Costco Wholesale Corporation (NASDAQ:COST – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 6,539 shares of the retailer’s stock, valued at approximately $6,117,000.

A number of other large investors have also recently made changes to their positions in the business. Brighton Jones LLC lifted its stake in Costco Wholesale by 12.3% in the fourth quarter. Brighton Jones LLC now owns 19,825 shares of the retailer’s stock worth $18,165,000 after acquiring an additional 2,172 shares during the period. Revolve Wealth Partners LLC increased its position in Costco Wholesale by 13.1% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,123 shares of the retailer’s stock valued at $1,029,000 after purchasing an additional 130 shares during the period. Sivia Capital Partners LLC raised its holdings in Costco Wholesale by 4.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,853 shares of the retailer’s stock worth $3,814,000 after purchasing an additional 165 shares in the last quarter. Pinnacle Wealth Planning Services Inc. raised its holdings in Costco Wholesale by 1.1% in the 2nd quarter. Pinnacle Wealth Planning Services Inc. now owns 2,110 shares of the retailer’s stock worth $2,089,000 after purchasing an additional 23 shares in the last quarter. Finally, Schnieders Capital Management LLC. lifted its position in shares of Costco Wholesale by 2.2% in the 2nd quarter. Schnieders Capital Management LLC. now owns 8,502 shares of the retailer’s stock worth $8,416,000 after purchasing an additional 182 shares during the period. 68.48% of the stock is currently owned by institutional investors.

Costco Wholesale Stock Down 1.2% Shares of Costco Wholesale stock opened at $928.48 on Thursday. Costco Wholesale Corporation has a 1 year low of $844.06 and a 1 year high of $1,096.50. The firm has a market cap of $411.76 billion, a price-to-earnings ratio of 46.70, a PEG ratio of 3.89 and a beta of 0.87. The company has a 50-day moving average of $944.65 and a 200 day moving average of $978.84. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.07 and a quick ratio of 0.61.

Costco Wholesale Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, August 7th. Shareholders of record on Friday, July 24th were paid a dividend of $1.47 per share. The ex-dividend date of this dividend was Friday, July 24th. This represents a $5.88 dividend on an annualized basis and a dividend yield of 0.6%. Costco Wholesale’s dividend payout ratio (DPR) is currently 29.58%. Key Headlines Impacting Costco Wholesale Here are the key news stories impacting Costco Wholesale this week:

Positive Sentiment: Strong sales momentum supports the investment case. Costco reported August net sales of $23.70 billion, up 9.9% year over year. Fourth-quarter sales rose 11.3% to $93.9 billion, while fiscal-year sales increased 10.2% to $297.3 billion. Total comparable sales grew 8.4% for the year, and digitally enabled sales jumped 20.9%. Costco Wholesale Corporation Reports August Sales Results Positive Sentiment: Analyst sentiment remains favorable. Mizuho reiterated a Buy rating and maintained a $1,100 price target, citing confidence in Costco’s membership-driven growth. Recent analyst targets generally remain above the current trading level, with a reported six-month median target of $1,125. Analyst Reiterates Buy on Costco Neutral Sentiment: Calendar effects clouded the monthly comparison. Costco said the later timing of Labor Day reduced August total and comparable sales growth by slightly less than 75 basis points. Underlying performance remained positive, but investors may look for confirmation in the next report. Negative Sentiment: Costco Next was abruptly discontinued. The company shut down the online Costco Next marketplace without notice. While the service is unlikely to materially affect near-term financial results, the move could disappoint members and remove a customer-engagement perk. Costco has ended this online service without notice Negative Sentiment: Regulatory uncertainty increased. The U.S. Department of Justice expanded an investigation into rising beef prices to include Costco and other major retailers. Potential reputational, legal, or margin-related consequences create an overhang, although no wrongdoing has been established. DOJ expands beef price investigation Negative Sentiment: Valuation leaves little room for disappointment. Costco trades at roughly 47 times earnings, with a PEG ratio above 4, and shares remain below their 50-day and 200-day moving averages. Insider activity has also consisted of sales rather than purchases in recent months, adding to investor caution. Insider Buying and Selling at Costco Wholesale In other news, Director Kenneth D. Denman sold 885 shares of Costco Wholesale stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $957.45, for a total transaction of $847,343.25. Following the completion of the transaction, the director directly owned 4,779 shares in the company, valued at approximately $4,575,653.55. This trade represents a 15.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.10% of the company’s stock.

Analyst Upgrades and Downgrades A number of equities research analysts have recently weighed in on COST shares. UBS Group lifted their target price on shares of Costco Wholesale from $1,205.00 to $1,275.00 and gave the company a “buy” rating in a research note on Wednesday, May 20th. TD Cowen restated a “buy” rating and issued a $1,175.00 price objective on shares of Costco Wholesale in a report on Wednesday, June 3rd. Sanford C. Bernstein lifted their price objective on Costco Wholesale from $1,192.00 to $1,194.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. Oppenheimer lifted their price objective on Costco Wholesale from $1,100.00 to $1,160.00 and gave the company an “outperform” rating in a research report on Tuesday, May 19th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,120.00 target price on shares of Costco Wholesale in a research report on Thursday, August 6th. Twenty-two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Costco Wholesale has a consensus rating of “Moderate Buy” and a consensus price target of $1,059.53.

Get Our Latest Stock Report on COST

(Free Report)

Costco Wholesale Corporation operates a global chain of membership-only warehouse clubs that sell a wide array of merchandise in bulk at discounted prices. The company’s product mix includes groceries, fresh and frozen food, household goods, electronics, apparel, and seasonal items, augmented by its prominent private-label brand, Kirkland Signature. Costco’s business model centers on annual membership fees and high-volume, low-margin sales, designed to drive repeat purchasing and strong customer loyalty among both consumers and small-business buyers.

Beyond merchandise, Costco provides a range of ancillary services that complement its warehouses, including gasoline stations, pharmacy and optical services, hearing aid centers, photo services, and travel and insurance products.

Featured Articles Five stocks we like better than Costco Wholesale Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test Want to see what other hedge funds are holding COST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Costco Wholesale Corporation (NASDAQ:COST – Free Report).

Receive News & Ratings for Costco Wholesale Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Costco Wholesale and related companies with MarketBeat.com's FREE daily email newsletter.

With the risk-free rate sitting near its highest level in years, Realty Income's legendary monthly dividend streak now faces a pressure test that even 674 consecutive payments cannot automatically survive.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Realty Income (NYSE:O | O Price Prediction) is set to pay shareholders again. The self-styled Monthly Dividend Company is distributing $0.271 per share on September 15, 2026, its 674th consecutive monthly dividend. That streak, combined with 115 consecutive quarterly increases and 133 total hikes since its 1994 NYSE listing, is the résumé investors buy into. The question for a scorecard: does the payout still deserve top marks with the 10-year Treasury at 4.75%?

Latest Payment and Yield Check The September check works out to an annualized forward dividend of $3.252, up in small monthly steps from $0.2695 as recently as October 2025. At a share price of $61.56, that pencils out to a 5.03% yield. Against a 4.75% risk-free rate, the income premium is just 28 basis points. Historically, O has offered a wider cushion, and that compression is the single biggest reason its grade is under pressure.

AFFO Backs the Payout GAAP optics look ugly: Q2 EPS of $0.37 missed the $0.42 estimate, and full-year net income guidance of $1.59 to $1.60 sits well below the dividend. For a REIT, though, AFFO is the right yardstick. AFFO per share grew 3.8% to $1.09 in Q2, and management raised the full-year midpoint to $4.44 to $4.45. That puts the AFFO payout ratio near 73%, leaving comfortable coverage and reinvestment capacity.

Portfolio and Balance Sheet Backing the Check The underlying real estate is doing its job. Portfolio occupancy stood at 98.8%, and 482 released units generated a blended rent recapture of 102.7%, with international recapture at 112.9%. Investment-grade tenants now account for 34% of annualized rent, up from 32% in Q1. On the balance sheet, net debt to EBITDAre sits at 5.4x, Fitch initiated with an A long-term issuer rating, and pro forma liquidity climbed to more than $5.7 billion. A $6 billion hyperscale data center joint venture with Cloud Capital adds a growth vector that pure retail net-lease peers cannot match.

Final Grade Grading on coverage, streak, portfolio quality, and credit, Realty Income still earns an A. Grading on relative yield, the picture softens: shares are up 12.67% year to date, which has trimmed the spread over Treasuries to a thin margin flagged in Barron’s recent look at the risks of the monthly income craze. Net grade: A-minus. Investors should watch cap rate trends and whether AFFO growth reaccelerates above 4% to justify paying up for the streak. If O’s thinner spread has you shopping the rest of the every-30-days aisle, we lined up seven of our favorite monthly payers in a free report: here.

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

All articles →

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.

"The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By combining Apogee's innovative science with AbbVie's proven development, regulatory and commercial capabilities, we aim to accelerate these programs and bring promising new treatment options to patients living with serious inflammatory and immunological diseases. We are excited to welcome the talented Apogee team to AbbVie and build on their important work."

Apogee's pipeline includes novel antibodies targeting multiple validated inflammatory pathways in large immunology and inflammation markets, including atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD).

Zumilokibart targets IL-13, a critical cytokine in type 2 inflammation, and a central driver of inflammatory diseases like AD and asthma. Specifically in AD, a majority of patients do not achieve simultaneous itch and skin improvement which represents an opportunity for the development of novel treatments that not only provide better skin clearance and itch resolution but also improve convenience with less frequent dosing. In its Phase 2 clinical trial, zumilokibart attained clinically significant results, with approximately two-thirds of patients on treatment achieving significant skin clearance at 16 weeks, along with notable improvements in itch reduction and overall disease control. These findings support its potential best-in-category profile, including strong efficacy and convenient dosing, in patients with AD. Longer-term data from the same trial also support maintenance regimens of either quarterly or twice a year dosing. The safety profile of zumilokibart is favorable and consistent with other medicines in its class, and the molecule has the potential to be evaluated in several additional inflammatory indications.

Beyond zumilokibart, Apogee has built a broader pipeline of novel antibodies targeting multiple validated inflammatory pathways. APG273 combines zumilokibart with APG333, an antibody that blocks thymic stromal lymphopoietin (TSLP), a signaling protein that acts as an early trigger of inflammation in the lungs. Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing. The Phase 1 data with APG333 and positive interim results from a Phase 1b study of zumilokibart in asthma, support the potential of the APG273 combination with quarterly or twice-yearly injections in asthma.

For additional background on the acquisition, please read the announcement press release here and view AbbVie's investor presentation here.

Financial Terms
AbbVie has acquired all outstanding Apogee common stock for $135.11 per share in cash, for a total equity value of approximately $10.9 billion. Apogee's common stock ceased trading on the NASDAQ stock exchange prior to market open on Sept. 3, 2026. AbbVie expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032.

Full-year 2026 Outlook
AbbVie is reaffirming its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07. This guidance includes a $0.14 per share dilutive impact related to the completed Apogee acquisition. AbbVie's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted.

AbbVie is reaffirming its previously issued 2026 third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88. AbbVie's 2026 third-quarter adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred in the quarter, as both cannot be reliably forecasted.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs generally identify forward-looking statements. Statements in this news release that are forward-looking may include, but are not limited to, statements regarding AbbVie's 2026 full-year and third-quarter adjusted diluted EPS guidance, the anticipated benefits of AbbVie's completed acquisition of Apogee and AbbVie's ability to successfully integrate Apogee's operations, employees and pipeline; the expected impact of the acquisition on AbbVie's adjusted diluted earnings per share; and the anticipated development, regulatory progress and commercial potential of Apogee's pipeline assets. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the amount and timing of acquired IPR&D and milestones expense; the risk that the anticipated benefits and synergies of the Apogee acquisition may not be realized, or may take longer to realize than expected; risks and costs related to integrating Apogee's business, employees and pipeline into AbbVie, including the possibility that such integration may be more difficult, time-consuming or costly than anticipated; the risk that acquired in-process research and development assets, including zumilokibart (APG777) and APG273, may not demonstrate the anticipated success, safety or efficacy in ongoing or future clinical trials, and that positive interim or earlier-stage results may not be predictive of results in later-stage or larger clinical trials; the risk of unknown or contingent liabilities assumed in connection with the acquisition; challenges to intellectual property; competition from other products; difficulties inherent in the research and development process; adverse litigation or government action; changes to laws and regulations applicable to our industry; the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2026 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE AbbVie

SummaryMicron Technology (MU) is rated Buy, driven by persistent AI-induced memory shortages extending beyond HBM into DRAM and NAND. AI server demand from Dell and HPE, coupled with supply constraints, positions MU for sustained elevated earnings through at least FY2028. DRAM is the core earnings driver, with HBM growth tightening conventional DRAM supply and NAND providing a near-term tailwind. My base case assigns $215 FY2028 EPS and a 7x multiple, supporting a $1,500 fair value—implying significant upside from current levels. Richard Drury/DigitalVision via Getty Images

Micron Technology (MU) has been an AI story for some time, but mostly an HBM story. GPUs need enormous amounts of high-bandwidth memory, Micron makes HBM, and that demand has helped turn what was once a brutally

283 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

USD/JPY has tumbled to 156.04, but JPMorgan's 164 year-end target survives because the pair remains inside its 155-165 central range. The US Dollar to Japanese Yen (USD/JPY) exchange rate has slumped to around 156.04 after a sudden Yen surge wiped more than four Yen from the pair in less than 48 hours.

The latest USD/JPY rate was down 1.81% on the day and 2.56% across 48 hours, trading only fractionally above the period's 156.00 low.

USD/JPY 48-Hour Price Chart

Image: USD/JPY 48h chart The fall looks severe on the short-term chart, but USD/JPY has not yet broken the range behind JPMorgan's year-end forecast.

JPMorgan expects the BoJ to raise rates roughly once per quarter, while assuming no substantial change in market expectations for Federal Reserve policy.

"If the BOJ continues to hike at roughly a quarterly pace while Fed hike expectations do not change materially, we think USD/JPY is likely to remain within the 155–165 range for the time being. This is our base case, and we maintain our USD/JPY targets of 160 at end-September and 164 at end-December."

At 156.04, USD/JPY is 1.04 Yen above the bottom of that range, while reaching 160 and 164 would require rebounds of approximately 2.5% and 5.1%, respectively.

JPMorgan said the OIS-implied probability of a September BoJ increase had already risen from 28% before the end-July intervention to 92%.

The latest surge therefore brings the market closer to the policy assumptions behind its central scenario rather than directly invalidating the 164 target.

USD/JPY Three-Month Chart

Image: USD to JPY rate three-month graph The three-month chart places USD/JPY much closer to its 155.27 low than July's 163.98 peak, with the pair also trading below its 20-day and 50-day moving averages.

Fed Pause Scenario Points to 157 JPMorgan's alternative scenario, in which the Fed pauses its rate increases, produces a lower USD/JPY range of 153-163.

"Based on the correlation between the 1y1y spread and USD/JPY observed at that time, the fair value of USD/JPY under a Fed pause scenario is around 157."

The current rate is already slightly below that estimate, although it remains inside the scenario range and near the 156-160 band discussed in our earlier Japanese Yen forecast.

JPMorgan accepts that an overshoot could temporarily push USD/JPY below 155, but adds: "In this scenario, however, we view the likelihood of a sharp yen appreciation—such as a move below 150—as low."

Near-Term US$/JPY Forecast: What Would Break the Range? A sustained move below 155 would require a stronger catalyst, with JPMorgan identifying Fed rate-cut expectations, an accelerated BoJ cycle that damages Japanese equities, a GPIF portfolio change or heavier official Yen buying.

Slower-than-priced BoJ tightening, stronger Fed hike expectations or renewed Japanese fiscal concerns could instead drive USD/JPY above 165.

US payrolls and the September Fed and BoJ decisions will now determine whether 156 becomes the starting point for a rebound or the first step towards JPMorgan's lower 153 boundary.

The EUR/USD rate has rebounded to 1.1610, while UniCredit sees a Fed-Treasury policy clash becoming a medium-term Dollar headwind. The Euro to Dollar (EUR/USD) exchange rate has climbed back to around 1.1610 after recovering from a 48-hour low of 1.1567.

The Euro is up roughly 0.2% on the day, although the prospect of another Federal Reserve rate hike continues to offer the Dollar near-term support.

Markets are assigning around a two-thirds probability to a September increase following Fed Chair Kevin Warsh's hawkish Jackson Hole speech.

UniCredit accepts that the repricing has helped the US currency, but strategist Roberto Mialich sees a more difficult medium-term picture.

Image: EUR/USD 48hr chart The 48-hour chart shows EUR/USD recovering steadily from below 1.1570, with the pair pushing towards the top of its recent range around 1.1610.

Fed Hike Expectations Support the Dollar UniCredit said: “The USD’s reaction has been exactly as expected, as Warsh’s speech has forced investors to reprice expectations regarding US monetary tightening – correcting the excessive optimism regarding limited rate-hike prospects following a series of weak US macro-data releases earlier this month.”

A rate increase by December was already fully priced when UniCredit published its assessment.

However, Mialich doubts that investors will price a much steeper tightening path without stronger US data or a further change in the Fed's language.

“That said, forward curves are unlikely to price in more aggressive monetary moves unless US data surprise sharply to the upside or the Fed signals an even more hawkish stance regarding the timing and magnitude of its tightening strategy.”

That gives the Dollar room to hold firm in the short term, but UniCredit's argument stretches beyond the next Fed meeting.

Treasury and Fed Objectives Could Collide The US Treasury is trying to contain borrowing costs as the budget deficit approaches 6.3% of GDP and public debt exceeds $40 trillion.

Its planned buyback operation will run from 9 September to 4 November, with purchases of longer-dated Treasuries financed through additional short-term bill issuance.

That strategy is intended to flatten the yield curve and reduce pressure at the long end.

A hawkish Fed would be pulling in the opposite direction by raising short-term rates and tightening financial conditions.

“Although the USD has gained from the repricing of overly dovish rate expectations, a collision between fiscal and monetary policy could emerge as a medium-term drag on the currency.”

Could “Sell America” Return? UniCredit argues that conflicting policy objectives could revive concerns about US fiscal credibility and encourage investors to reduce their Dollar exposure.

“However, the risk of a collision course between US fiscal and monetary policies may increase significantly if they were to pursue opposing goals on interest rates. This could act as a headwind for the USD in the medium term – regardless of signs of potential escalation in the Middle East – by further fuelling “sell America” trades and the de-dollarization process.”

The beneficiaries could include the Euro, precious metals, real estate and selected cryptocurrencies.

For EUR/USD, UniCredit offers a direction rather than a formal price target.

Its view also fits the longer-term bias in our latest bank forecast survey, which sees the pair rising towards 1.18 over the coming quarters.

The next tests will be US payroll and inflation data, the September Fed decision and the Treasury buyback beginning on 9 September.

Markets will also watch the shape of the US yield curve and whether fiscal concerns start to outweigh the Dollar's near-term interest-rate advantage.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Magnite (NASDAQ:MGNI), the largest independent sell-side advertising company, today announced major milestones across its live streaming business, cementing its position as the premier partner for live streaming advertising. As media owners prepare for a massive fall lineup, anchored by the return of NFL and college football, Magnite is scaling a global marketplace for live, built on a foundation of verified, event-level transparency for the industry's biggest live moments.

Historically buyers have struggled to differentiate between truly real-time live content and shoulder content. Magnite’s Live Scheduler allows media owners to signal upcoming live events well in advance, giving buyers the foresight needed to plan and execute campaigns with verified live inventory, so they can reach engaged audiences precisely when key moments happen.

Since launching Live Scheduler last November, 37 media owners globally have utilized the technology to seamlessly schedule and monetize over 4,000 live events, including high-stakes broadcasts like the FIFA World Cup, NFL Monday Night Football, the NHL Playoffs, as well as major cultural moments including the Academy Awards.

“Live programming combines highly valuable content and highly attentive audiences, creating powerful opportunities for advertisers,” said Jamie Power, SVP, Addressable Sales at Disney Advertising. “Supporting those moments requires scalable, reliable technology that can keep pace with audience demand. Magnite helps us enable and manage the unique demands of live streaming while simultaneously creating more opportunities for the marketplace."

By streamlining access and overcoming the technical complexity of live CTV execution, Magnite is opening up incremental growth for publishers. From January to July, Magnite has seen a 56% year over year increase in global live sports ad spend with over 5,800 advertisers spending on live sports inventory that did not spend in the year prior.

“Live events bring people together around the moments and conversations they care about most, creating meaningful opportunities for brands to connect with audiences,” said Holly Dunn, Managing Partner, Head of Investment & Activation, Havas Media Network North America. “As audiences and media continue to fragment, marketers are increasingly looking to sports and live programming as a core part of the media mix, not simply a one-off activation. These environments offer something increasingly valuable by creating shared experiences at scale and connecting brands to culture in real time. Magnite helps make these opportunities more accessible, giving brands the flexibility to reach the right audiences and engage with the moments that matter”.

Magnite’s live strength is underpinned by several key capabilities designed to drive seamless monetization:

Precision activation: Unlike typical CTV deals that bundle live inventory with general supply, Magnite supports sport-specific, daypart-aligned, high-priority line items, backed by pacing algorithms built to ensure smooth delivery.Infrastructure built for viewership spikes: Live Stream Acceleration (LSA) automates traffic distribution and decisioning during rapid live viewer surges, managing the performance and optimization challenges that happen during high-concurrency ad breaks.Access via programmatic or agentic workflows: Buyers can easily access Magnite's live marketplace via programmatic channels or discover relevant live events for advertisers through agentic buying workflows via Magnite’s Buyer Agent.
“Live streaming offers advertisers an unprecedented opportunity to capture massive, highly engaged audiences in real time,” said Mike Laband, Group SVP of Revenue at Magnite. “We are democratizing access to this live inventory in a way that works seamlessly for both sides of the market. By continuously innovating across our supply infrastructure, we are unlocking net-new monetization opportunities for media owners while providing buyers with an effortless, transparent doorway into verified live media.”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

Media Contact:
Charlstie Veith
[email protected]

Investor Contact:
Nick Kormeluk
[email protected]

SLB Today

$58.09 +0.94 (+1.65%)

As of 09/2/2026 03:59 PM Eastern

This is a fair market value price provided by Massive. Learn more.

$31.64▼

$60.462.03%

28.06

$61.35

SLB NYSE: SLB just made a clear bet that data centers, not oil wells, define its next decade. On Aug. 31, the company announced it has signed an agreement to acquire Kelvion, a century-old thermal-management specialist, for approximately $3.4 billion in cash and the assumption of approximately $0.7 billion of debt, bringing the total transaction value to approximately $4.1 billion.

Most coverage framed it as another modular infrastructure tuck-in to the company's existing oil services business. That undersells it.

Get SLB alerts:

Paired with SLB's expanding NVIDIA NASDAQ: NVDA partnership and its rapidly scaling Data Center Solutions unit, the Kelvion deal signals SLB is building a genuine second growth engine. Management is targeting $4.5 billion to $5 billion in 2028 revenue for the combined Data Center Solutions business. The real question for investors: Is that engine big enough to change how the market values the company's stock?

SLB’s $4.1 Billion Kelvion Acquisition Adds Data Center GrowthKelvion isn't a startup chasing the AI boom. Founded more than 100 years ago, the company is expected to generate $2.3 billion to $2.4 billion in revenue in 2026 and $350 million to $400 million in adjusted EBITDA. Data centers are already its largest and fastest-growing segment, projected to contribute $1.2 billion to $1.3 billion of that revenue this year.

Kelvion booked $1.5 billion in orders in the first half of 2026 alone, up 43% year-over-year. This is a scaled, profitable business SLB is buying at a reasonable multiple.

SLB’s NVIDIA Partnership Strengthens Its Data Center StrategyThe strategic logic builds directly on work SLB was already doing. In March, SLB expanded its partnership with NVIDIA to become the modular design partner for NVIDIA's DSX AI factories, alongside a joint "AI Factory for Energy" initiative.

SLB's Data Center Solutions revenue has grown at a compound annual rate exceeding 90% since 2024, with more than 2 gigawatts of delivered capacity. Cooling was the missing piece. CEO Olivier Le Peuch said the deal "more than doubles" SLB's revenue opportunity per gigawatt delivered, turning modular construction into a fuller-service data-center platform rather than a single-discipline contractor.

Why SLB’s Kelvion Deal Can Be Accretive Despite Higher DebtSLB is financing the deal with existing cash and debt, not new shares, which matters for the accretion language in the press release. Because share count won't change, earnings per share (EPS) accretion depends only on whether Kelvion's earnings outpace the after-tax cost of the new debt.

At roughly 11 times 2026 EBITDA before synergies—an implied yield near 9%—Kelvion clears that bar comfortably against SLB's investment-grade borrowing costs, even before the $120 million in annual synergies management expects within three years. SLB says leverage stays within its 1.5x net debt-to-EBITDA target, preserving the balance sheet discipline it has emphasized to shareholders.

SLB Stock Faces a Perception Gap as Oilfield Earnings DeclineThis company's last four earnings reports reveal an earnings-per-share (EPS) story that provides important context for the Kelvion deal. SLB has beaten consensus EPS estimates in recent quarters, but adjusted EPS continues to decline year over year (YOY). It was down 26% in the second quarter of 2026 and 28% in the first quarter, as oilfield pricing softened and Middle East disruptions weighed on the Production Systems segment.

Full-year 2025 adjusted EPS fell approximately 24%. Headlines will continue to focus on the beats. The more relevant fact is that the company's legacy business is under real, sustained pressure. This raises the stakes on Kelvion rather than lowering them. A credible, scaling second growth engine matters more, not less, when the core business is shrinking.

Can SLB’s Data Center Business Become a Meaningful Growth Engine?Even at the high end of the $4.5 billion to $5 billion 2028 target, data centers would represent roughly 12% to 14% of SLB's current revenue base of approximately $36 billion. That's meaningful, but not yet transformative.

Kelvion alone won't re-rate SLB into a technology multiple. But layered onto sustained 90%-plus growth in Data Center Solutions, an active NVIDIA partnership, and now a profitable thermal-management platform, it's a credible enough trajectory that investors should start pricing SLB as two businesses rather than one — even if the second one is still the smaller of the pair.

SLB Stock Technical Analysis: Can $55 Hold as Support?The chart adds a technical layer to that argument. SLB shares spiked from the mid-$50s to a 52-week high over $60 immediately after the Kelvion announcement, then pulled back to close near $57.16. That's a classic sell-the-news retracement following an initial pop.

Even after that pullback, SLB trades comfortably above both its 50-day ($50.35) and 200-day ($48.84) simple moving averages, and both are trending higher, which is a constructive setup technically.

The prior range top near $55, tested repeatedly from March through June before a summer sell-off dragged shares to the mid-$40s, is now acting as support rather than resistance. As long as SLB holds that zone, the technical trend still favors buyers digesting the news rather than a market losing conviction in the deal.

SLB Stock Outlook: Kelvion Deal Could Reshape the Growth Story81st Percentile

Moderate Buy

5.6% Upside

Healthy

Strong

0.86 N/A

27.60%

See Full Analysis

Kelvion won't turn SLB into a data-center pure play overnight.

Investors also must consider that a closing timeline stretching into the first half of 2027 leaves plenty of room for integration risk and regulatory review to intrude.

But the deal sharpens a thesis that's been building since the NVIDIA expansion. SLB is diversifying away from a legacy business that's still losing ground YOY and financing the move without diluting shareholders.

Since the announcement, the SLB analyst forecasts on MarketBeat show three analysts have reiterated a Buy or equivalent rating on SLB. The chart suggests the market is only just now starting to notice.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in SLB Right Now?Before you consider SLB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SLB wasn't on the list.

While SLB currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Vancouver, British Columbia, September 3, 2026 – TheNewswire – Frequency Exchange Corp. (TSXV: FREQ | OTC: FRECF | FSE: YC6) (“Frequency Exchange” or the “Company”) is pleased to announce that NIKKI, the Company’s wearable wellness device, has been approved for sale on Best Buy Marketplace, the third-party seller platform available through BestBuy.ca and the Best Buy app. The Company is targeting an initial Canadian launch in Q4 2026.

The launch is being advanced in collaboration with Ripple Distribution and TKG Partners, Frequency Exchange’s retail distribution partner. Ripple/TKG is working with the Company to expand NIKKI’s presence across major retailers in Canada and select international markets. Frequency Exchange views Best Buy as a significant first step in expanding its NIKKI wellness platform into mainstream consumer retail and establishing additional distribution channels.

Best Buy already serves consumers through an established ecosystem of leading wearable and health-tracking brands, including Apple, WHOOP, Oura and Fitbit. NIKKI is designed to complement this ecosystem by offering consumers a frequency-based wellness platform alongside the tracking and monitoring capabilities of their existing devices.

NIKKI delivers frequency-based wellness programs designed to support sleep, stress, recovery and overall vitality, and can be used independently or alongside existing wearable and health-tracking devices.

Stephen Davis, CEO of Frequency Exchange, commented: “This represents a significant advancement for NIKKI and for our commercialization strategy. As we prepare for NIKKI’s planned launch on Best Buy Marketplace, we are also encouraged to have approximately CAD$600,000 in commitments already secured toward the first tranche of our current financing. This early support comes at an important time as we move into the next stage of execution, with Best Buy Marketplace, additional retail opportunities and international distribution all advancing.”

Click Image To View Full Size

Davis added: “Best Buy has helped bring wearable health-tracking technology into the mainstream, giving consumers access to leading devices that track areas such as sleep, stress, activity and recovery. With NIKKI, we believe Best Buy now has the opportunity to help introduce the next evolution of wearable wellness, a technology designed to support the very areas those devices are tracking. Just as Best Buy helped consumers discover wearable tracking technology, we believe it can play an important role in introducing NIKKI as the companion to that technology.”

The Company believes the planned Q4 launch represents a pivotal commercial milestone for NIKKI. As NIKKI becomes available to consumers through Best Buy Marketplace, the technology is also expected to gain additional exposure through Superhuman 2: REBIRTH, a major documentary focused on frequencies, while Frequency Exchange continues to advance NIKKI’s introduction to consumers through its access to more than 7,000 wellness clinics in the United States.

Together, these initiatives are expected to position NIKKI across three complementary channels — mainstream retail, practitioner access and consumer media — creating multiple avenues for consumer discovery, adoption and long-term brand development.

About Ripple Distribution and TKG Partners

Ripple Distribution and TKG Partners are an end-to-end retail distribution partner focused on building brands through channel development, sales and retail expansion across North American and international markets. Ripple/TKG maintains relationships with a broad network of major retailers that the Company believes represent potential future opportunities for NIKKI.

About Frequency Exchange Corp.

  Frequency Exchange Corp. (TSXV: FREQ | OTC: FRECF | FSE: YC6) is a technology company building the next generation of wearable digital wellness solutions through its flagship platform, NIKKI®. Unlike traditional wearable devices that primarily monitor health metrics, NIKKI delivers personalized frequency-based wellness programs designed to support sleep, stress, recovery, energy and overall wellbeing. Originally developed through research supporting individuals living with Lyme disease, NIKKI has evolved into a scalable digital wellness platform addressing some of today’s largest global health challenges.

  For additional information, please visit www.frequencyexchangecorp.com or www.wearenikki.com.

  Investor Contacts:

  Frequency Exchange Corp.                        FREmedica Technologies Inc.

Stephen Davis                                         Nicole Sullivan

Chief Executive Officer                         President

[email protected]        [email protected]

604-684-2181                                         604-684-2181

  Forward-Looking Information

  This news release contains forward-looking statements within the meaning of applicable securities laws. These statements reflect the Company’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements.

  Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

  Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

SHENZHEN, CHINA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

The NDA for indication AD has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which effectively shortened the product's review process and accelerated the marketing approval for the AD indication.

From “First Topical JAK Inhibitor” to Indication Expansion, Lumirix® Continues to Deliver Clinical Value

In January 2026, Lumirix® was approved for marketing by the NMPA, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo. The approval of this NDA for the additional indication of AD offers a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*.

Previously, Lumirix® achieved positive results in a randomized, double-blind, placebo-controlled phase III clinical trial in China for mild to moderate AD:

Robust Efficacy: Lumirix® successfully met its primary endpoint— a significantly higher proportion of patients treated with Lumirix® achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with Lumirix® was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: the severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, Lumirix® was safe and well-tolerated. *Based on Phase III clinical data from China and overseas.

Building the AD “treatment + care” Solution to Strengthen Dermavon's Skin Health Layout

AD is a chronic, recurrent and inflammatory dermatologic disease. According to CIC Report, there were over 54 million AD patients in China in 2024[1]. To address the needs of AD patients from treatment to daily care, Dermavon has built a comprehensive “treatment + care” solution:

Topical formulation: Lumirix® (mild-to-moderate AD) – Marketed in ChinaInjectable biological agent: Comekibart Injection (moderate-to-severe AD) – Under NDA review in ChinaOral small molecule targeted drug: CMS-D001 (moderate-to-severe AD) – Phase II clinical trialDaily repair: Heling Soothing Product Series – Marketed in China Simultaneously, the indication expansion of Lumirix® will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.

About AD

AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.

More Information About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream is a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, as well as the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate[3,4].

On 2 December 2022, Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream, obtaining an exclusive license to develop, register and commercialize the product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the product in the Territory. Dermavon has sublicensed the relevant rights for the product outside of Mainland China to the Group (excluding Dermavon).

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

References

1.China Insights Consultancy’s industrial report

2.The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib

3.The EMA approval information for vitiligo indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

4.The EMA approval information for AD indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/opzelurar-ruxolitinib-cream-becomes-first-steroid-free-topical

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: [email protected]

Website: https://web.cms.net.cn/en/home/

 | Source: Saia, Inc.

JOHNS CREEK, Ga., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Saia, Inc. (Nasdaq: SAIA) is providing LTL shipment and tonnage data for the first two months of the third quarter. In July 2026, LTL shipments per workday increased 0.8%, LTL tonnage per workday increased 7.8% and LTL weight per shipment increased 7.0%, each compared to July 2025. In August 2026, LTL shipments per workday increased 1.1%, LTL tonnage per workday increased 8.7% and LTL weight per shipment increased 7.5%, each compared to August 2025.

These changes are summarized in the table below:

 July 2026
versus July 2025 August 2026
versus August 2025 Quarter to Date (QTD) 2026
versus QTD 2025LTL Shipments per workday0.8% 1.1% 1.0%LTL Tonnage per workday7.8% 8.7% 8.3%LTL Weight per shipment7.0% 7.5% 7.2%       Actual third quarter and annual shipments, tonnage and weight per shipment could differ materially from the data expressed in this press release, including by reason of the risk factors included in Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in other filings with the Securities and Exchange Commission. The information herein speaks as of the date of this press release and is subject to change. Saia is under no obligation, and expressly disclaims any obligation to update or alter such information, whether as a result of new information, future events, or otherwise, except as required by law.

Saia, Inc. (Nasdaq: SAIA) offers customers a wide range of less-than-truckload, brokered truckload, expedited transportation and other logistics services. With headquarters in Georgia, Saia LTL Freight operates 218 terminals with national service. For more information on Saia, Inc. visit the Investor Relations section at www.saia.com/about-us/investor-relations.

Cautionary Note Regarding Forward-Looking Statements

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand the future prospects of a company and make informed investment decisions. This news release may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “may,” “plan,” “predict,” “believe,” “should,” “potential” and similar words or expressions are intended to identify forward-looking statements. Investors should not place undue reliance on forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. All forward-looking statements reflect the present expectation of future events of our management as of the date of this news release and are subject to a number of important factors, risks, uncertainties and assumptions that could cause actual results to differ materially from those described in any forward-looking statements. These factors, risks, uncertainties and assumptions include, but are not limited to, (1) general economic conditions including downturns or inflationary periods in the business cycle; (2) operation within a highly competitive industry and the adverse impact from downward pricing pressures, including in connection with fuel surcharges, and other factors; (3) industry-wide external factors largely out of our control; (4) cost and availability of qualified drivers, dock workers, mechanics and other employees, purchased transportation and fuel; (5) inflationary increases in expenses and corresponding reductions of profitability; (6) cost and availability of diesel fuel and fuel surcharges; (7) cost and availability of insurance coverage and claims expenses and other expense volatility, including for personal injury, cargo loss and damage, workers’ compensation, employment and group health plan claims; (8) failure to successfully execute the strategy to expand our service geography; (9) unexpected liabilities resulting from the acquisition of real estate assets; (10) costs and liabilities from the disruption in or failure of our technology or equipment essential to our operations, including as a result of cyber incidents, security breaches, malware or ransomware attacks; (11) risks arising from remote work, including increased risk of related cybersecurity incidents; (12) failure to keep pace with technological developments; (13) liabilities and costs arising from the use of artificial intelligence; (14) labor relations, including the adverse impact should a portion of our workforce become unionized; (15) cost, availability and resale value of real property and revenue equipment; (16) supply chain disruption and delays on new equipment delivery; (17) changes in U.S. trade policy and the impact of tariffs; (18) capacity and highway infrastructure constraints; (19) risks arising from international business operations and relationships; (20) seasonal factors, harsh weather and disasters caused by climate change; (21) the creditworthiness of our customers and their ability to pay for services; (22) our need for capital and uncertainty of the credit markets; (23) the possibility of defaults under our debt agreements, including violation of financial covenants; (24) inaccuracies and changes to estimates and assumptions used in preparing our financial statements; (25) dependence on key employees; (26) employee turnover from changes to compensation and benefits or market factors; (27) increased costs of healthcare benefits; (28) damage to our reputation from adverse publicity, including from the use of or impact from social media; (29) failure to achieve acquisition synergies or disruption to our business due to such acquisitions; (30) the effect of litigation and class action lawsuits arising from the operation of our business, including the possibility of claims or judgments in excess of our insurance coverages or that result in increases in the cost of insurance coverage or that preclude us from obtaining adequate insurance coverage in the future; (31) the potential of higher corporate taxes and new regulations, including with respect to climate change, employment and labor law, healthcare and securities regulation; (32) unforeseen costs from new and existing data privacy laws; (33) the effect of governmental regulations, including hours of service and licensing compliance for drivers, engine emissions, the Compliance, Safety, Accountability (CSA) initiative, regulations of the Food and Drug Administration and Homeland Security, and healthcare and environmental regulations; (34) changes in accounting and financial standards or practices; (35) widespread outbreak of an illness or any other communicable disease; (36) international conflicts and geopolitical instability; (37) evolving stakeholder expectations regarding environmental and social issues; (38) government shutdown or failure to fund services; (39) provisions in our governing documents and Delaware law that may have anti-takeover effects; (40) issuances of equity that would dilute stock ownership; (41) weakness, disruption or loss of confidence in financial or credit markets; and (42) other financial, operational and legal risks and uncertainties detailed from time to time in the Company’s SEC filings.

As a result of these and other factors, no assurance can be given as to our future results and achievements. Accordingly, a forward-looking statement is neither a prediction nor a guarantee of future events or circumstances and those future events or circumstances may not occur. You should not place undue reliance on the forward-looking statements, which speak only as of the date of this news release. We are under no obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.

CONTACT:Saia, Inc. Matthew Batteh Executive Vice President and Chief Financial Officer
[email protected]  

Coherent's stock just absorbed a brutal pullback while its forward earnings estimates climbed higher, a rare split that forces a direct question about whether the optical AI infrastructure trade still has legs at this price.

Coherent (NYSE:COHR | COHR Price Prediction) looks compelling at $268.64, with the stock having pulled back 8.74% in the past week even as forward earnings estimates keep marching higher. That combination of cooling price and heating fundamentals is exactly the moment worth having a view on.

Coherent is a photonics manufacturer whose lasers, transceivers, and optical components sit at the physical layer of the AI datacenter. Its Datacenter and Communications segment now accounts for 79% of total sales and grew 59% year over year in the June quarter. A run from roughly $87.80 a year ago to the high $330s in August, followed by a fade back to the current level, has left the stock in a genuine debate zone.

Why the AI Bandwidth Trade Still Has Room The bull case rests on a supply-constrained business selling into a demand curve that keeps steepening. Q4 revenue hit $2.05 billion, non-GAAP EPS came in at $1.74, and non-GAAP operating margin expanded to 21.8% from 18.0% a year earlier. Management guided Q1 FY27 revenue to between $2.2 billion and $2.4 billion and is targeting a quarterly revenue run rate above $3 billion by the end of fiscal 2027.

Bookings hit a record, customer orders now extend into calendar 2028, and CEO Jim Anderson said “AI datacenter architectures increasingly transition from copper to optical connectivity.” That copper-to-optical shift is the same tailwind lifting the non-chip AI suppliers we profiled in a free report on seven picks-and-shovels names powering the buildout. New platforms in 1.6T transceivers, optical circuit switches, CPO, and thermal solutions all ramp into fiscal 2027, and analysts have raised the FY27 EPS estimate from $8.0885 ninety days ago to $9.4061.

Where the Valuation Gets Uncomfortable The bear case starts with the multiple. A trailing P/E of 65 leaves little margin for error, and FY26 operating cash flow fell 87.45% to $79.5 million as capital expenditures jumped 150.18% to $1.1 billion. Long-term debt sits at $3.2 billion.

Concentration compounds the risk. Nearly four fifths of revenue depends on hyperscaler AI capex, industrial revenue was roughly flat pro forma for the year, and Q3 industrial fell 16.1%. Any push out of CPO, indium phosphide yield stumbles, or slowdown in 800G and 1.6T adoption hits a stock that already tripled off its September 2025 base.

Argument for Patience The hold view says the setup is real but the entry is awkward. Shares are down 6.77% over the past month, and the next print will test whether guidance ranges tighten. Coherent Photon Link launches at an industry event on September 21, CPO revenue begins in fiscal Q2 2027, and Thermodyte cooling ramps in the second half of calendar 2027. Waiting one quarter costs optionality but buys visibility on capex payback and margin trajectory toward the 42% gross margin target.

What the Numbers Say About the Setup Coherent currently trades at $268.64 against an average analyst price target of $397.63 across 21 analysts, implying roughly 48% upside, with a consensus Buy rating. Targets are one data point among many.

Performance context matters. COHR is up 45.55% year to date and 205.97% over one year, versus roughly 11.99% YTD and 18.13% over one year for the S&P 500. FY26 revenue reached $7.12 billion, up 22.51%, with net income of $805 million.

Why the Setup Still Looks Favorable Here At $268.64, the setup warrants a closer look. Here is why.

The path to appreciation is mechanical. Internal indium phosphide capacity doubles by the end of the current quarter, one quarter ahead of plan, and doubles again by the end of calendar 2027. That directly translates into transceiver volume for 800G and 1.6T, the two products in tightest demand. Layer in CPO revenue starting fiscal Q2 2027 with NVIDIA-linked ultra-high-power lasers, plus optical circuit switching addressing a $4 billion opportunity, and the FY28 consensus of $13.9489 in EPS looks bracketed by real orders.

The risk/reward at this entry is favorable because the stock has already absorbed a roughly 20% drawdown from the August print while forward estimates rose. What would invalidate the call: a CPO push out, a 1.6T adoption stall, or a hyperscaler capex reset. Investors should watch quarterly indium phosphide output, 1.6T mix, and CPO revenue recognition in the December quarter.

Coherent is compounding earnings faster than its price is rising, and that is the crux of the bull case.

Contact [email protected] for any questions or corrections.

Backpack US appointed Multicoin Capital cofounder Kyle Samani to its board of directors on Sept. 2 as the company expands its regulated financial services in the United States.

Summary

Backpack US appointed Multicoin Capital cofounder Kyle Samani to its board of directors on Wednesday. Samani stepped back from Multicoin in February while retaining an advisory relationship with the firm. He remains chairman of Forward Industries, a publicly traded company pursuing a Solana treasury strategy. Backpack says the appointment will support its expansion across regulated U.S. and onchain financial markets. Backpack reports serving users across 150 countries and processing more than $450 billion in volume. Samani is an early Solana investor and a longtime supporter of blockchain based capital markets. He stepped back from managing Multicoin Capital in February 2026 but retained an advisory relationship with the venture firm.

The appointment gives Samani a governance role at Backpack US rather than an executive position. Backpack did not disclose his term, compensation, committee assignments or specific responsibilities.

Backpack CEO Armani Ferrante said Samani’s experience with decentralized networks and crypto regulation made him a suitable adviser. Ferrante said Samani understands the company’s plan to connect traditional financial markets with blockchain infrastructure.

https://twitter.com/Backpack/status/2095144073602478223?s=20

Samani brings Solana and venture capital experience Samani cofounded Multicoin Capital in 2017 and helped establish the firm as an early institutional investor in Solana. Multicoin has also backed projects focused on decentralized finance, blockchain infrastructure and crypto trading.

Samani announced his departure from Multicoin’s daily management in February. He said he planned to explore other areas of technology while continuing to advise the firm.

He also remains chairman of Forward Industries, a publicly traded company pursuing a Solana treasury strategy. Forward adopted the strategy after completing a $1.65 billion private placement led by Multicoin, Galaxy Digital and Jump Crypto in 2025.

The strategy is designed to increase the company’s exposure to SOL and expand its SOL holdings per share. Those objectives are corporate targets rather than guaranteed results.

Samani’s Forward Industries position gives him experience overseeing a public company with a digital asset treasury. It also connects him closely to the Solana ecosystem, which remains central to several Backpack products.

Backpack did not explain how it would address potential conflicts involving Samani’s roles at Forward and Multicoin. The company also did not disclose whether he would be excluded from decisions involving Multicoin portfolio companies.

Backpack US focuses on regulated financial products Backpack describes itself as a financial services group connecting crypto markets with traditional finance. Its products include a crypto exchange, a self custody wallet and Backpack Securities.

The company says Backpack Securities combines a regulated brokerage with a tokenization platform. Its stated objective is to provide access to conventional securities and blockchain based asset distribution within one product environment.

Backpack did not identify the U.S. licenses held by each group entity in its appointment announcement. It also did not provide registration numbers or explain which entity would handle brokerage, custody, tokenization and trade execution.

Companies providing securities brokerage services in the United States generally must register with the Securities and Exchange Commission and become members of the Financial Industry Regulatory Authority unless an exemption applies. Specific registrations should therefore be confirmed against official regulatory records as Backpack expands its services.

The company has already followed a regulated expansion strategy in Europe. Backpack acquired FTX EU and assumed responsibility for returning funds to eligible former customers. The company later addressed questions surrounding its purchase of FTX EU.

Backpack subsequently launched its European exchange through a Cyprus based entity operating under the Markets in Financial Instruments Directive framework. That expansion gave the company a regulated route for offering crypto derivatives to eligible European customers.

Equity trading supports Backpack’s broader strategy Backpack said Samani’s appointment followed the launch of continuous trading for several equity products. It named SpaceX, Micron, SanDisk and SK Hynix among the assets available through its services.

The company described its offering as trading in “real” equities alongside a growing range of tokenized stocks. However, the announcement did not provide a complete explanation of the execution venues, custody structure, settlement system or shareholder rights attached to each product.

Those distinctions matter because traditional shares, tokenized shares and price tracking instruments do not always provide identical rights. Depending on the structure, investors may not receive direct voting rights, dividend claims or ownership of the underlying security.

Other crypto platforms are developing similar services. Kraken recently introduced more than 7,000 traditional U.S. stocks for eligible European customers alongside its tokenized xStocks products.

Kraken has also allowed eligible traders to use certain tokenized stocks as collateral for futures and margin positions. The development reflects growing competition among crypto companies seeking to combine securities exposure with blockchain based trading systems.

Samani said the future of capital markets involves combining “institutional risk controls with onchain efficiency and transparency.” His comment represents his assessment of the market’s direction, not a confirmed outcome for Backpack’s products.

Board appointments support Backpack’s U.S. expansion Samani joins a board that also includes former acting SEC chairman Michael Piwowar, whom Backpack appointed earlier in 2026. The appointments add venture capital, public company and securities regulation experience to Backpack’s governance structure.

Backpack said its leadership additions would support the creation of regulated infrastructure connecting traditional and digital assets. It has not announced new product approvals or regulatory licenses resulting from Samani’s appointment.

The company reports serving customers in more than 150 countries and regions and processing over $450 billion in trading volume. These figures come from Backpack and were not accompanied by an independently audited breakdown in the board announcement.

Backpack has not provided a fixed schedule for expanding its U.S. equity or tokenized asset services. It also has not disclosed whether Samani’s appointment is connected to a specific product launch, acquisition or licensing application.

The next relevant updates will involve Backpack’s U.S. registrations, customer eligibility rules and product structure. Further disclosures may clarify which entities handle securities execution, custody and token issuance.

Until then, the appointment represents a governance step supporting Backpack’s stated U.S. strategy. It does not by itself confirm regulatory clearance for additional securities or tokenized asset products.

—New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease—

—New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via COMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)—

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that five abstracts highlighting data from its respiratory portfolio have been accepted for presentation at the European Respiratory Society (ERS) Congress 2026 taking place Sept. 5–9, 2026, in Barcelona.

Presentation highlights include a late-breaking abstract from the Phase 3b ENCORE study, which evaluated 12 months of treatment with ARIKAYCE® (amikacin liposome inhalation suspension) plus multidrug therapy (azithromycin 250 mg and ethambutol 15 mg/kg) in patients diagnosed with a new occurrence of Mycobacterium avium complex (MAC) lung infection who had not received antibiotics. The scientific program will also include a post hoc analysis of COMPERA 2.0 risk score data from the Phase 2 study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). Additionally, data will be presented on the psychosocial burden of exacerbations, treatment patterns, and healthcare resource utilization associated with bronchiectasis, as well as from a post hoc analysis of the Phase 3 ASPEN study of BRINSUPRI® (brensocatib), the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB).

"The data presented at the ERS Congress 2026 reflect our commitment to advancing research and improving outcomes for patients with serious respiratory diseases," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "We are particularly pleased to present findings from our Phase 3b ENCORE study addressing rates of recurrence following treatment for NTM lung disease, an important challenge in long-term disease management. These findings, together with data from our broader respiratory portfolio, contribute to a growing body of evidence that can help shape the future of care for patients who have long faced limited treatment options." 

Presentations:

Oral Session OA1207, Sunday, Sept. 6, 9:30 a.m. CEST to 10:45 a.m. CEST (3:30 a.m. ET to 4:45 a.m. ET)

Late-Breaking Abstract: Microbiologic Outcomes and Recurrence in Patients With Newly Diagnosed Mycobacterium avium Complex Lung Disease (MACLD) in the Phase 3b ENCORE Trial Poster Session PA908, Sunday, Sept. 6, 8:00 a.m. CEST to 9:30 a.m. CEST (2:00 a.m. ET to 3:30 a.m. ET)

COMPERA 2.0 Risk Assessment of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH): A Post Hoc Analysis of a Phase 2 Study Poster Session PA1839, Sunday, Sept. 6, 12:30 p.m. CEST to 2:00 p.m. CEST (6:30 a.m. ET to 8:00 a.m. ET)

Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacteria (NTM) Infection: A Post Hoc Analysis of the ASPEN Trial Poster Session PA1840, Sunday, Sept. 6, 12:30 p.m. CEST to 2:00 p.m. CEST (6:30 a.m. ET to 8:00 a.m. ET)

Quantifying the Psychosocial Impact of Exacerbations in Bronchiectasis: A European Patient-Centered Study Poster Session PA2883, Monday, Sept. 7, 8:00 a.m. CEST to 9:00 a.m. CEST (2:00 a.m. ET to 3:00 a.m. ET)

Treatment Patterns and Healthcare Resource Utilization Associated With Bronchiectasis and Pulmonary Exacerbations in Spain About ARIKAYCE 

ARIKAYCE® is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE™ liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI). 

About PARI Pharma and the Lamira® Nebulizer System 

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care. 

About BRINSUPRI 

BRINSUPRI® (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in NCFB. The therapy is approved in the United States as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age or older. In the European Union and United Kingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. In Japan, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of patients with non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years and older.

About TPIP

Treprostinil palmitil inhalation powder (TPIP) is an investigational dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Designed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being developed as once-daily therapy for the treatment of patients with pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF). TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.

BOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONSARIKAYCE has been associated with an increased risk of respiratory adverse reactions, 
including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of 
underlying pulmonary disease that have led to hospitalizations in some cases.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage patients as medically appropriate.

Bronchospasm has been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate. 

Exacerbations of underlying pulmonary disease has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions: Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

Ototoxicity has been reported with the use of ARIKAYCE in the clinical trials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo) were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated with background regimen alone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9% in the background regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the background regimen alone arm). Closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment with ARIKAYCE. If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.

Nephrotoxicity was observed during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been associated with the aminoglycosides. Close monitoring of patients with known or suspected renal dysfunction may be needed when prescribing ARIKAYCE.

Neuromuscular Blockade: Patients with neuromuscular disorders were not enrolled in ARIKAYCE clinical trials. Patients with known or suspected neuromuscular disorders, such as myasthenia gravis, should be closely monitored since aminoglycosides may aggravate muscle weakness by blocking the release of acetylcholine at neuromuscular junctions.

Embryo-Fetal Toxicity: Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated with total, irreversible, bilateral congenital deafness in pediatric patients exposed in utero. Patients who use ARIKAYCE during pregnancy, or become pregnant while taking ARIKAYCE should be apprised of the potential hazard to the fetus.

Contraindications: ARIKAYCE is contraindicated in patients with known hypersensitivity to any aminoglycoside.

Most Common Adverse Reactions: The most common adverse reactions in Trial 1 at an incidence ≥5% for patients using ARIKAYCE plus background regimen compared to patients treated with background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs 1%), and chest discomfort (5% vs 3%).

Drug Interactions: Avoid concomitant use of ARIKAYCE with medications associated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or intravenous mannitol.

Overdosage: Adverse reactions specifically associated with overdose of ARIKAYCE have not been identified. Acute toxicity should be treated with immediate withdrawal of ARIKAYCE, and baseline tests of renal function should be undertaken. Hemodialysis may be helpful in removing amikacin from the body. In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment.

U.S. INDICATION 

LIMITED POPULATION: ARIKAYCE® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.

This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitation of Use:

ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Patients are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call the Company at 1-844-4-INSMED. 

Please see Full Prescribing Information. 

INDICATION AND IMPORTANT SAFETY INFORMATION FOR BRINSUPRI IN THE U.S.

U.S. Indication  

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings. 

Gingival and Periodontal Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene. 

Live Attenuated Vaccines
It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI. 

ADVERSE REACTIONS
The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions. 

Less Common Adverse Reactions
Liver Function Test Elevations
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. 

Skin Cancers
In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. 

Alopecia
In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6%, respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women. 

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition. 

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age. 

Please see full US Prescribing Information. 

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Forward-looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: risk that interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or may be interpreted differently if additional data are disclosed; failure to successfully conduct future clinical trials for our marketed products or our product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates; development of unexpected safety or efficacy concerns related to our marketed products or our product candidates; risks that our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected; failure to maintain U.S., European or Japanese approval for ARIKAYCE or U.S. or European approval for BRINSUPRI; our inability to obtain full approval of ARIKAYCE from the FDA or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for our product candidates in the U.S., Europe or Japan, for ARIKAYCE outside of the U.S., Europe and Japan, including separate regulatory approval for the Lamira® Nebulizer System in each market and for each usage, or for BRINSUPRI outside of the U.S. and Europe; and failure to successfully commercialize our product candidates, if approved by applicable regulatory authorities, or to maintain applicable regulatory approvals for our product candidates, if approved.

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission (SEC).

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contact:

Investors:
Sara Bonstein
Chief Financial Officer
[email protected] 

Media:
Claire Mulhearn
Vice President, Corporate Communications
[email protected]

SOURCE Insmed Incorporated

Both data center REITs just paid shareholders, both ride the same AI wave, but their dividend scorecards look nothing alike. One has raised its payout for over a decade while the other has frozen shareholders out for four years despite…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Two data center REITs just paid investors, and their scorecards on payout coverage look very different. Digital Realty Trust (NYSE:DLR | DLR Price Prediction) sends shareholders $1.22 per share on September 30, 2026, the same quarterly rate it has paid since March 2022. Equinix (NASDAQ:EQIX) paid $5.16 per share on September 16, 2026, part of a raise that pushed the payout 10% higher and extended its 11th consecutive year of dividend growth. Same industry, same AI tailwind, two grades on the coverage math.

Payout Coverage: Who Has More Room to Run Equinix guides full-year 2026 AFFO per share to $42.69 to $43.29 against expected cash dividends of roughly $2.039 billion. CFO Olivier Leonetti confirmed the target on the July call: “we have a payout ratio in the 50% range, so we will have a sizable retained cash flow.” That retained cash flow funds a capital budget of $5 billion to $6 billion for the year without stressing the dividend.

Digital Realty’s coverage is thinner on a headline basis but improving fast. FY2026 Core FFO per share guidance sits at $8.00 to $8.10 against an indicated annual dividend of $4.88, implying a payout in the low 60s. Management raised the Core FFO per share range excluding net promote income to $8.15 to $8.20 after Q2, calling it the “second consecutive year of double digit core FFO per share growth.”

Growth Streak vs. Frozen Payout DLR’s $1.22 quarterly rate has not moved in more than four years. The company last raised the dividend from $1.16 to $1.22 with the March 2022 payment, and every declaration since has held the line. That stall now stretches across a period where Core FFO per share rose from $1.77 in Q1 2025 to $2.04 in Q1 2026. The company is earning more, but shareholders are not getting more in the mailbox.

Equinix moved the other way. The quarterly dividend stepped from $4.69 to $5.16 with the February 2026 payment, and the run of raises now spans over a decade. Management explicitly linked future increases to earnings, telling investors “dividend growth to approximate AFFO per share growth” through 2029, with AFFO per share expected to compound at 9% to 12% annually.

Balance Sheet Behind the Checks Coverage is only as durable as the balance sheet. Equinix carries net leverage of 3.6 times adjusted EBITDA with $7.7 billion of liquidity. Digital Realty runs hotter at 4.7 times debt to adjusted EBITDA, though CFO Matt Mercier flagged that as “well below our long-term threshold” and paired it with roughly $6 billion of liquidity. DLR’s backlog reached a record $1.4 billion at DLR share, roughly 30% of in-place data center rent, which management said should support “multiple years of double-digit growth.” The capital funding that backlog has to come from somewhere, and the picks-and-shovels names on the other side of the meter, power, cooling, and networking, are the subject of a free report we put together on seven AI infrastructure suppliers that aren’t chipmakers.

Total Return Scorecard Investors have noticed the difference. EQIX is up 36.15% year to date and 33.49% over one year. DLR trails with a 20.05% year-to-date gain and 12.45% over one year. Market caps reflect the gap: $99.4 billion for Equinix versus $67.3 billion for Digital Realty.

Grading the Coverage On payout coverage alone, Equinix earns an A. A payout ratio in the 50% range, an 11-year growth streak, and explicit guidance tying future raises to double-digit AFFO growth is the textbook profile. Digital Realty grades a C. The FFO math works, the growth is accelerating, and leverage is dropping, but a dividend frozen for four consecutive years while earnings compound sends a mixed message about capital priorities. The next signal to watch is whether DLR’s board finally moves the $1.22 rate as 2026 Core FFO per share crosses $8.15 to $8.20. Until then, EQIX owns the scorecard.

Contact [email protected] for any questions or corrections.

Investors Who Purchased The Simply Good Foods Company Common Stock Between October 24, 2024 and April 8, 2026 May Seek Appointment as Lead Plaintiff by October 13, 2026  | Source: Wolf Popper LLP

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP, a law firm representing investors in securities litigation, announces that a securities class action lawsuit has been filed against The Simply Good Foods Company (“Simply Good” or the “Company”) (NASDAQ: SMPL).

The lawsuit is brought on behalf of investors who purchased or otherwise acquired Simply Good common stock between October 24, 2024 and April 8, 2026, inclusive. Investors seeking appointment as lead plaintiff must file a motion with the Court by October 13, 2026.

The case, Monroe County Employees’ Retirement System v. The Simply Good Foods Company, No. 26-cv-06971, is pending in the United States District Court for the Southern District of New York.

WHAT IS THE CASE ABOUT?

The lawsuit concerns Simply Good’s approximately $280 million acquisition of Only What You Need, Inc. (“OWYN”) and statements the Company made regarding OWYN’s integration, business performance, and future prospects.

According to the complaint, Simply Good’s positive statements failed to disclose significant problems affecting the OWYN business, including:

the loss of key managerial personnel following the acquisition;an increasingly layered organizational structure created in response to those personnel losses;product-quality problems involving a new pea-protein supplier that allegedly affected the taste, texture, and shelf life of OWYN products;weakening consumer demand, negative product reviews, and the loss of distributor relationships;increased discounting and promotional activity designed to stimulate sales, which allegedly pressured margins without producing the intended turnaround; andreductions in brand support and marketing that allegedly contributed to further weakness in OWYN sales. The complaint alleges that these problems undermined the strategic and financial rationale for the OWYN acquisition while Simply Good continued to make favorable statements about OWYN and the progress of its integration.

WHAT HAPPENED?

On October 23, 2025, Simply Good disclosed that OWYN’s sales growth had slowed and that consumer consumption had been adversely affected by a product-quality issue. According to the complaint, Simply Good shares fell more than 17% that day.

On April 9, 2026, Simply Good reported that OWYN quarterly sales had declined nearly 17% year over year and recorded an approximately $187 million impairment charge related to OWYN. Management also acknowledged that certain strategic decisions had ultimately weakened the business’s performance. Simply Good shares declined more than 27% over the next two trading days.

The lawsuit alleges that, as a result of defendants’ materially false and misleading statements and omissions, investors purchased Simply Good shares at artificially inflated prices.

WHAT CAN SIMPLY GOOD FOODS INVESTORS DO?

If you purchased or acquired Simply Good common stock between October 24, 2024 and April 8, 2026 and suffered a loss, you may contact Adam Savett at (212) 451-9655 or [email protected] to discuss your legal rights.

Investors who wish to seek appointment as lead plaintiff must file a motion with the Court no later than October 13, 2026. You do not need to serve as lead plaintiff to participate in any potential recovery.

Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper’s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm’s website at www.wolfpopper.com.

May Be Considered Attorney Advertising in Certain Jurisdictions.
Prior Results Do Not Guarantee a Similar Outcome.

Wolf Popper LLP
Adam Savett
570 Lexington Avenue
New York, NY 10022
Tel.: (212) 451-9655
Email: [email protected] 

GE Vernova (GEV +2.60%) was spun off from General Electric a little more than two years ago. By 2036, we'll look back at that breakup as one of the better corporate decisions GE ever made.

If you're unfamiliar, GE Vernova sells gas turbines, wind turbines, nuclear technology, transformers, grid equipment, and the software and services needed to keep much of it running. That means the company doesn't have to predict exactly how the U.S. will generate electricity 10 years from now, because it can make money from nearly all of it. And with electricity demand accelerating, that's a very good business to be in.

Image source: Getty Images.

The numbers are already getting big GE Vernova generated $38 billion in revenue in 2025. Management now expects $45.5 billion to $46.5 billion in 2026, representing a pretty dramatic increase in just one year.

More recently, the company ended the second quarter with a huge $176 billion backlog. Orders reached $24.2 billion during the quarter, up 88%, with particularly strong demand coming from the Power and Electrification businesses.

Premium Feature

Moneyball Superscore

81/100

Today's Change

(

2.60

%) $

23.41

Current Price

$

921.94

That backlog gives you something many industrial companies don't have: visibility. GE Vernova already has customers lining up years in advance for the equipment they'll need to generate and move electricity. And, of course, artificial intelligence (AI) adds another catalyst.

Data center-related orders exceeded $5 billion during the first half of 2026, more than double the company's total for all of 2025. If AI continues driving the construction of enormous data centers, utilities will need more generating capacity, transformers, substations, switchgear, and transmission equipment. GE Vernova sells all of it.

The natural gas angle GE Vernova's gas turbine backlog and slot reservations reached 116 gigawatts during the second quarter, up from 100 gigawatts just three months earlier. Management expects that number to reach at least 125 gigawatts by year-end.

The company is responding by expanding annual gas-turbine output from 20 gigawatts in 2026, with plans to reach 30 gigawatts by 2030. GE Vernova has more than 7,000 gas turbines installed worldwide, creating a deep recurring service business, too. Its total services backlog now stands at $88.5 billion. And I suspect that in 10 years, services will account for an even larger share of total revenue.

The grid could be the real winner Electrification may ultimately become GE Vernova's most important growth engine. Its equipment backlog in that business reached $35 billion in 2025, more than quadrupling in four years. Management expects it to roughly double again by 2028.

This is one of the easiest parts of the GE Vernova thesis to understand. Whether electricity comes from natural gas, solar, wind, or nuclear, somebody still has to move it from the power plant to the customer. The grid needs transformers, switchgear, and high-voltage equipment. GE Vernova supplies those products.

And then there's nuclear GE Vernova Hitachi's BWRX-300 small modular reactor (SMR) is now under construction in Ontario. The company expects to finish construction on this first SMR by the end of 2029 and begin commercial operations by the end of 2030.

If that project proves SMRs can be built economically and on schedule, GE Vernova could enter the 2030s with another substantial growth business. That's not something I'm factoring heavily into the stock today. But by 2036, nuclear power could be considerably more important to this company than the market currently appreciates.

Not everything will work GE Vernova's Wind business had a $275 million loss on an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) basis during the second quarter, compared with a $165 million loss a year earlier. Wind orders also fell roughly 40%. That's a reminder that growth hasn't been uniform.

The bigger concern, though, is valuation. GE Vernova today isn't the same bargain it was shortly after the 2024 spinoff. But I'm much more interested in what the business could look like in 2036 than what investors are willing to pay for it next quarter. By then, I expect GE Vernova to be a substantially larger company with a much bigger installed base, significantly more recurring service revenue, and major businesses spanning gas, grid infrastructure, and potentially nuclear.

I wouldn't be surprised to see annual revenue well above $70 billion by then. That's my estimate, not management's expectation, and it doesn't require spectacular growth. Going from roughly $46 billion in 2026 to $70 billion in 2036 requires only about 4.3% annualized growth.

The bigger opportunity, though, could come from margins and cash flow. GE Vernova is already targeting a 20% adjusted EBITDA margin by 2028, with revenue of $38 billion and an 8.4% adjusted EBITDA margin in 2025. If management can combine moderate long-term revenue growth with that level of profitability, GE Vernova could generate enormous cash flows during the next decade. And that's ultimately why I'm bullish on the stock for the long haul.

D L Carlson Investment Group Inc. acquired a new stake in Tesla, Inc. (NASDAQ:TSLA – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 16,899 shares of the electric vehicle producer’s stock, valued at approximately $7,108,000. Tesla makes up about 1.1% of D L Carlson Investment Group Inc.’s portfolio, making the stock its 20th biggest position.

A number of other institutional investors and hedge funds have also modified their holdings of TSLA. Crestwood Advisors Group LLC lifted its position in Tesla by 34.7% during the fourth quarter. Crestwood Advisors Group LLC now owns 19,567 shares of the electric vehicle producer’s stock valued at $8,799,000 after purchasing an additional 5,039 shares during the period. Wealthquest Corp purchased a new stake in Tesla during the 4th quarter valued at $1,035,000. Private Capital Advisors Inc. lifted its holdings in shares of Tesla by 139.3% during the 4th quarter. Private Capital Advisors Inc. now owns 21,331 shares of the electric vehicle producer’s stock valued at $9,593,000 after buying an additional 12,417 shares during the period. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Tesla by 34.8% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 64,481 shares of the electric vehicle producer’s stock worth $28,998,000 after buying an additional 16,652 shares during the last quarter. Finally, Canada Post Corp Registered Pension Plan grew its holdings in shares of Tesla by 26.6% in the fourth quarter. Canada Post Corp Registered Pension Plan now owns 70,955 shares of the electric vehicle producer’s stock worth $31,910,000 after acquiring an additional 14,900 shares during the period. Institutional investors own 66.20% of the company’s stock.

Tesla Stock Up 0.3% Shares of NASDAQ TSLA opened at $357.01 on Thursday. The company has a current ratio of 1.94, a quick ratio of 1.55 and a debt-to-equity ratio of 0.09. Tesla, Inc. has a 12-month low of $297.38 and a 12-month high of $498.83. The firm’s 50-day moving average price is $358.71 and its 200-day moving average price is $383.59. The stock has a market capitalization of $1.41 trillion, a price-to-earnings ratio of 330.57, a P/E/G ratio of 17.98 and a beta of 1.84.

Tesla (NASDAQ:TSLA – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The electric vehicle producer reported $0.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.17). The company had revenue of $28.24 billion during the quarter, compared to the consensus estimate of $26.42 billion. Tesla had a net margin of 3.67% and a return on equity of 3.82%. Tesla’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 earnings per share. On average, equities research analysts anticipate that Tesla, Inc. will post 0.88 EPS for the current fiscal year. Wall Street Analyst Weigh In TSLA has been the topic of a number of recent research reports. Citizens Jmp assumed coverage on Tesla in a report on Thursday, July 9th. They issued a “market perform” rating on the stock. Mizuho set a $450.00 price target on Tesla and gave the company an “outperform” rating in a research note on Thursday, July 23rd. Robert W. Baird set a $475.00 price target on shares of Tesla in a research report on Monday, July 27th. Evercore raised shares of Tesla from a “hold” rating to an “outperform” rating in a report on Friday, June 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Tesla in a research report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, eighteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Tesla has an average rating of “Hold” and a consensus price target of $401.74.

Read Our Latest Stock Analysis on TSLA

Insider Buying and Selling In other Tesla news, CFO Vaibhav Taneja sold 2,606 shares of Tesla stock in a transaction on Monday, June 8th. The shares were sold at an average price of $402.20, for a total transaction of $1,048,133.20. Following the completion of the transaction, the chief financial officer directly owned 22,039 shares of the company’s stock, valued at $8,864,085.80. The trade was a 10.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 19.90% of the stock is owned by insiders.

More Tesla News Here are the key news stories impacting Tesla this week:

Positive Sentiment: Cybercab and robotaxi optimism: Tesla has registered 45 purpose-built Cybercabs in Texas, adding credibility to its planned autonomous ride-hailing rollout. Investors are looking for evidence that the vehicle can scale commercially and generate high-margin software or mobility revenue. Tesla’s Cybercab Fleet Hits 45 Ahead of Austin Launch Positive Sentiment: Potential energy-business tailwind: New U.S. power-grid policy restricting certain Chinese equipment could benefit Tesla’s energy-storage operations, providing an additional growth avenue beyond vehicles. Tesla stock investors stand to gain from U.S. power grid Positive Sentiment: Commercial vehicle opportunity: Einride plans to deploy at least 75 Tesla Semi trucks in 2026 and 500 by 2027, giving investors a clearer timeline for a potentially meaningful commercial-vehicle business. Tesla Gets First 2026 Delivery Timeline For Landmark 500 Semi Order Neutral Sentiment: Event expectations are elevated: Morgan Stanley maintained a Hold rating and a $400 price target, warning that a limited initial Cybercab fleet could trigger a selloff. The event must demonstrate more than a prototype—particularly safety, regulatory progress, production capacity and a credible launch schedule. Tesla Cybercab Momentum Balanced by Execution Risks Negative Sentiment: Sales momentum is uneven: China-made EV sales rose only 3.6% year over year in August, sharply slower than July. European registrations were mixed, with major declines in markets including Norway, Sweden, Spain and Portugal despite strong gains in France and Denmark. Tesla’s China-made EV sales extend growth streak, but momentum fades Negative Sentiment: Autonomy and valuation concerns remain: A reported fatal Illinois crash has renewed scrutiny of Tesla’s FSD technology, while Waymo and Zoox are expanding robotaxi services. Analysts and commentators also question whether Tesla’s roughly $1.4 trillion valuation is justified given pressured margins, slowing growth and a PE ratio above 300. Tesla’s FSD Faces Fresh Scrutiny After Fatal Illinois Crash Negative Sentiment: Solar retrenchment: Tesla stopped taking Solar Roof orders and has not reported solar deployment figures since late 2023, reinforcing concerns that some non-automotive initiatives are being deprioritized. Tesla Stopped Reporting Solar Numbers 10 Quarters Ago Tesla Company Profile (Free Report)

Tesla, Inc (NASDAQ: TSLA) is an American company that designs, manufactures and sells electric vehicles, energy generation and energy storage products. Founded in 2003 by Martin Eberhard and Marc Tarpenning, Tesla grew into a vertically integrated mobility and clean‑energy company with Elon Musk serving as its chief executive officer. The company’s stated mission is to accelerate the world’s transition to sustainable energy, reflected in its combined focus on electric drivetrains, battery technology, renewable energy products and software.

Tesla’s automotive business includes a lineup of battery‑electric vehicles and related services.

Featured Stories Five stocks we like better than Tesla Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test

Receive News & Ratings for Tesla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesla and related companies with MarketBeat.com's FREE daily email newsletter.

Shares in Tesla (TSLA +0.26%) rose by 18.2% in August, according to data from S&P Global Market Intelligence. The move comes as the narrative around the stock, notably its robotaxi rollout, improved throughout the month. And the good news is there's a real possibility of more good news flowing in the future.

Tesla's reset of expectations To be clear, Tesla's second-quarter report released at the end of July wasn't great. A good recovery in electric vehicle (EV) deliveries was accompanied by a strong increase in costs associated with incentivizing sales, robotaxi and Optimus development, commodity costs, and AI initiatives. These costs and an unfavorable EV sales mix (relatively more sales of lower-margin vehicles) led to margin compression.

At the same time, Tesla is ramping capital expenditures, partly to support the ramp in its robotaxi business, and investors are concerned that the rollout isn't progressing as planned.

Premium Feature

Moneyball Superscore

65/100

Today's Change

(

0.26

%) $

0.92

Current Price

$

357.01

A change in narrative for Tesla Narratives matter in investing, and they matter a lot for growth stocks, whose main value-creating events lie ahead. There's a reason why many management teams emphasize underpromising and overdelivering: it often leads to a significant rerating of the stock.

However, in Tesla's case, it's fair to argue that the robotaxi rollout hasn't met the expectations previously laid out by CEO Elon Musk, neither in terms of fleet size nor city deployment. Robotaxis did not cover half the U.S. population by the end of 2025. With only six cities with unsupervised robotaxis (Bay Area robotaxis are supervised) so far in 2026, Tesla looks highly unlikely to be deployed in "dozens of cities, dozens of major cities by the end of the year," as Musk said they would be in January.

That said, it's important to recognize how technologically challenging the rollout is, and the critical need to achieve a level of safety and operational functioning so that its robotaxi, including the dedicated robotaxi, Cybercab, can be scaled. Any scaling of a flawed model will only magnify and increase the absolute number of incidents.

Image source: Tesla.

Moreover, management spent the last two earnings calls redirecting the narrative away from fleet size and city expansions and toward the development of its next major version of full self-driving (FSD) software, v15, and overall miles driven under unsupervised robotaxi operations. All told, the narrative around robotaxis has arguably shifted to focus on v15 and miles driven, rather than fleet size and city deployments.

This change in narrative means it's likely the market will now reward any positive development on robotaxi/Cybercab, and that's exactly what's happened recently.

Positive robotaxi developments Fortunately, Tesla has had good news to report on it lately: Nevada lifted the cap on robotaxi vehicles in Clark County from 10 to 5,000 vehicles in August Tesla announced the launch event for the Cybercab, which just took place. Safety data on unsupervised robotaxis (updated in mid August and current through mid July) arguably show an exemplary safety record, albeit with a relatively small data set compared to Waymo. These events helped raise confidence in Tesla's robotaxi rollout, and with expectations now reset, more positive news flow on robotaxi is likely to be rewarded by the market.

Capital Investment Advisory Services LLC lifted its position in Amazon.com, Inc. (NASDAQ:AMZN – Free Report) by 1.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 114,946 shares of the e-commerce giant’s stock after buying an additional 1,995 shares during the period. Amazon.com makes up 1.7% of Capital Investment Advisory Services LLC’s holdings, making the stock its 13th largest position. Capital Investment Advisory Services LLC’s holdings in Amazon.com were worth $27,396,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Amazon.com by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 832,274,556 shares of the e-commerce giant’s stock worth $158,348,557,000 after acquiring an additional 8,913,959 shares in the last quarter. State Street Corp raised its position in shares of Amazon.com by 1.8% during the fourth quarter. State Street Corp now owns 388,653,121 shares of the e-commerce giant’s stock worth $89,708,913,000 after purchasing an additional 6,971,680 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Amazon.com by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 225,120,994 shares of the e-commerce giant’s stock valued at $51,753,622,000 after purchasing an additional 2,479,324 shares during the last quarter. Norges Bank purchased a new stake in shares of Amazon.com during the fourth quarter valued at $32,868,735,000. Finally, Auto Owners Insurance Co boosted its position in shares of Amazon.com by 27,376.7% in the 4th quarter. Auto Owners Insurance Co now owns 98,448,885 shares of the e-commerce giant’s stock valued at $2,272,397,000 after purchasing an additional 98,090,585 shares during the period. 72.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amazon.com In other Amazon.com news, CFO Brian T. Olsavsky sold 6,172 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $260.31, for a total transaction of $1,606,633.32. Following the transaction, the chief financial officer directly owned 109,207 shares of the company’s stock, valued at $28,427,674.17. This represents a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP David Zapolsky sold 9,258 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $259.77, for a total value of $2,404,950.66. Following the sale, the senior vice president owned 41,190 shares of the company’s stock, valued at approximately $10,699,926.30. This trade represents a 18.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 70,589 shares of company stock worth $18,314,015 in the last ninety days. Company insiders own 8.90% of the company’s stock.

Wall Street Analysts Forecast Growth AMZN has been the topic of several recent analyst reports. TD Cowen restated a “buy” rating and set a $350.00 price objective (up from $340.00) on shares of Amazon.com in a report on Friday, July 31st. The Goldman Sachs Group restated a “buy” rating and set a $375.00 price target (up from $335.00) on shares of Amazon.com in a report on Friday, July 31st. Telsey Advisory Group set a $335.00 price objective on shares of Amazon.com and gave the stock an “outperform” rating in a research note on Friday, July 31st. Phillip Securities cut Amazon.com from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $300.00 price target on shares of Amazon.com in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, fifty-six have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $323.09. View Our Latest Analysis on AMZN

Amazon.com Trading Up 0.0% Shares of NASDAQ AMZN opened at $254.98 on Thursday. The business has a 50 day simple moving average of $252.99 and a 200 day simple moving average of $241.79. Amazon.com, Inc. has a 52 week low of $196.00 and a 52 week high of $287.20. The stock has a market cap of $2.75 trillion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.97 and a beta of 1.44. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.87 and a current ratio of 1.03.

Amazon.com (NASDAQ:AMZN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The e-commerce giant reported $5.75 earnings per share for the quarter, beating the consensus estimate of $1.82 by $3.93. The firm had revenue of $200.61 billion for the quarter, compared to analyst estimates of $197.03 billion. Amazon.com had a net margin of 17.44% and a return on equity of 18.00%. The company’s revenue for the quarter was up 19.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.68 earnings per share. On average, research analysts predict that Amazon.com, Inc. will post 8.05 earnings per share for the current fiscal year.

Key Stories Impacting Amazon.com Here are the key news stories impacting Amazon.com this week:

Positive Sentiment: Institutional investors are signaling confidence in Amazon’s AI infrastructure opportunity. Stanley Druckenmiller increased Duquesne’s AMZN position more than tenfold, while Philippe Laffont’s Coatue expanded its stake 49%, reinforcing the thesis that AWS will benefit from sustained AI-computing demand. Stanley Druckenmiller Increased Amazon More Than 10-Fold and Opened an AMD Position Positive Sentiment: AWS growth, accelerating e-commerce revenue and expanding AI infrastructure investment remain key bullish factors. Analysts continue to see substantial upside, including a reiterated $350 price target, although Amazon’s heavy capital expenditures could pressure near-term cash returns. Amazon Retains Top Pick Status Positive Sentiment: Amazon’s new YouTube Shopping partnership allows creators to tag products and earn affiliate commissions, potentially expanding social-commerce traffic and advertising opportunities. Zoox’s expansion into additional U.S. markets also adds a longer-term mobility growth option. How Could Amazon Gain From New Creator Shopping Tools? Neutral Sentiment: The Justice Department requested beef-pricing data from Amazon and other major retailers as part of an investigation into meat-industry pricing. Amazon is not accused of wrongdoing in the reports, but the inquiry adds regulatory visibility. DOJ Expands Beef Price Investigation Negative Sentiment: The FTC and 22 states allege Amazon manipulated advertising auctions and overcharged roughly 1.2 million advertisers by more than $20 billion. Potential penalties, pricing changes and pressure on the high-margin advertising business are the most immediate downside risks. FTC Sues Amazon, Alleging It Overcharged Advertisers Negative Sentiment: Amazon is facing additional workforce friction, including planned corporate job cuts and a one-day Teamsters strike at its large Riverside warehouse. These developments could increase reputational, labor and operating-cost concerns. About Amazon.com (Free Report)

Amazon.com, Inc is a diversified technology and retail company best known for its e-commerce marketplace and broad portfolio of consumer and enterprise services. Founded by Jeff Bezos in 1994 and headquartered in Seattle, Washington, the company launched as an online bookseller and expanded into a global retail platform that sells products directly to consumers and provides a marketplace for third-party sellers. Over time Amazon has grown beyond retail into areas including cloud computing, digital media, devices and logistics.

Key businesses and offerings include Amazon’s online marketplace and fulfillment services, the Amazon Prime membership program (which bundles expedited shipping with streaming and other benefits), Amazon Web Services (AWS) which supplies on-demand cloud computing and storage to businesses and public-sector customers, and a range of content and advertising services such as Prime Video and Amazon Advertising.

See Also Five stocks we like better than Amazon.com Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test

Receive News & Ratings for Amazon.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amazon.com and related companies with MarketBeat.com's FREE daily email newsletter.

Microsoft (NASDAQ: MSFT) has declared its next quarterly dividend of $0.91 per share payable Thursday, September 10, 2026, to shareholders of record on August 20, 2026. 

Investors holding 100 MSFT shares as of the ex-dividend date will receive $91 next week. As such, the payment is unchanged from the previous two payments this year issued on June 11 and March 12.  

Microsoft quarterly dividend history. Source: Microsoft At a share price of $496.82 as of press time, September 3, and a quarterly dividend of $0.91 per share, you would need approximately 109.89 Microsoft shares to round up the dividend to $100. In other words, it would require an investment of about $54,590, or about 110 shares. 

If the corporation does not increase the payout, the yearly Microsoft stock dividend for 2026 will total exactly $364.

Microsoft Corp. dividend profile Microsoft boasts among the most consistent dividend track records in the technology sector, with a forward yield of 0.73% and an annualized dividend of $3.88 per share. 

What’s more, the software leader has increased its dividend for 24 consecutive years, and with a conservative forward payout ratio of 18.45%, it has considerable flexibility to continue raising its payouts.

Historically, Microsoft shares have also recovered quickly following their ex-dividend dates, taking an average of just 1.9 days. While the company’s 0.73% dividend yield is below the broader technology sector average of 1.37%, Microsoft has emphasized consistent dividend growth and long-term share price appreciation rather than pursuing a high-yield strategy.

That approach has paid off in 2026 too. The stock is up around 5% year-to-date as of press time, and a $10,000 investment in Microsoft at the start of the year, assuming all dividends were reinvested, would now be worth approximately $10,348. That translates into $48.73 in reinvested dividends and $299.98 in capital gains.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!